Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, et al
Here's a breakdown of what I can share based on available information: Key Facts and Mechanism Dual Agonist: Tirzepatide is the first-in-class dual GIP and GLP-1 receptor agonist
Risks of Improper IGF-1 LR3 Dosing Because IGF-1 stimulates growth pathways, excessive or unsupervised dosing may increase risks, including: Hypoglycemia (low blood sugar) Edema Joint discomfort Nerve compression symptoms Potential overstimulation of mitogenic pathways IGF-1 signaling is also involved in cellular proliferation
Ask your provider about the dosing schedule, how to administer the medication correctly, and what to do if a dose is missed
NewsFDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers Associated Press, July 23, 2026